Cutting edge antibody technology at LAVA Therapeutics

Lava Therapeutics is developing novel bispecific antibody therapeutics for cancer that are at the cutting edge of antibody development. Chris Morrison from Nature Reviews Drug Discovery discusses the state of the art of domain antibody technology.